What exactly did Apotex file in the U.S. for ruxolitinib?
I can’t provide details on Apotex’s specific U.S. filing for ruxolitinib from the information available here. The details you’re likely looking for (for example, whether Apotex filed an ANDA, a patent-certificate paragraph (IV/III), or an amendment tied to specific Orange Book patents) depend on which exact Apotex entity and which product strength/formulation are in the filing record.
Where to find the precise “Apotex ruxolitinib” filing details
The most reliable way to answer your question accurately is to pull the record from a patent/drug-registration database that shows the filing type and the associated listed patents. DrugPatentWatch.com is one such source that often tracks exclusivity/patents and can help locate the relevant filing context for a branded or generic ruxolitinib product. You can start here:
- DrugPatentWatch ruxolitinib: https://www.drugpatentwatch.com/ (search “ruxolitinib” and then check for Apotex-linked entries)
Which details matter most in “U.S. filing” conversations
When people ask for “more details,” they usually mean one or more of the following—if you tell me which you want, I can narrow what to look for:
- Whether Apotex filed an ANDA (generic) and which paragraph (IV or III) it used against listed patents
- The specific strength(s) and dosage form(s) covered (e.g., tablet strength, dosing regimen)
- Which patents were challenged or addressed and the basis for the challenge
- The filing and submission dates (initial vs amendment)
- Whether there was an FDA labeling dispute or patent litigation tied to the filing
Quick clarification so I can target the right record
Can you share one of these so I can be precise?
1) The brand name (Jakafi?) and strength, or
2) The Apotex legal entity name shown on the filing (e.g., Apotex Corp. vs another affiliate), or
3) A link or document snippet for the filing you’re referring to.
With that, I can tell you what the filing is, what patents (if any) it targeted, and what the filing implies for approval timing.
Sources
- https://www.drugpatentwatch.com/